Trials / Recruiting
RecruitingNCT05963347
Go-CHOP as the Frontline Therapy for PTCL
A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Golidocitinib | Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib. |
| DRUG | CHOP Regimen | CHOP will be administered in a 21-day cycle for a maximum of 6 cycles. |
Timeline
- Start date
- 2023-08-03
- Primary completion
- 2025-07-30
- Completion
- 2026-07-31
- First posted
- 2023-07-27
- Last updated
- 2023-09-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05963347. Inclusion in this directory is not an endorsement.